Codexis, Inc. filings document the company's public-company disclosures as a Nasdaq-listed biotechnology issuer focused on enzymatic solutions for therapeutics manufacturing. Recent 8-K reports furnish quarterly and annual operating results, financial-condition updates, business-update exhibits, and material event disclosures tied to organizational streamlining and the ECO Synthesis platform.
Proxy materials describe annual meeting voting, board classes and committee membership, director elections, executive compensation, and other governance matters. The filing record also identifies Codexis common stock, par value $0.0001 per share, trading under CDXS on the Nasdaq Global Select Market.
CODEXIS, INC. director Rahul Singhvi was granted a stock option covering 66,350 shares of common stock. The option has an exercise price of $2.48 per share and expires on June 17, 2036.
The award vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, as long as he continues serving as a director on that vesting date. Following this grant, his option holdings from this award total 66,350 shares.
CODEXIS, INC. director Esther Martinborough reported receiving a stock option grant covering 66,350 shares of common stock at an exercise price of $2.48 per share. The option vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to her continued board service, and expires on June 17, 2036. Following this grant, she holds options for 66,350 shares directly.
CODEXIS, INC. director Stephen George Dilly reported receiving a grant of stock options. The award covers 66,350 options to buy Common Stock at an exercise price of $2.48 per share, with 66,350 derivative securities shown as held after the transaction.
These options were granted as compensation, not bought on the open market, and carry no upfront cost to the director. They vest and become exercisable for all shares on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided he continues serving as a director through that vesting date.
CODEXIS, INC. director Raymond De Vre received a grant of stock options covering 66,350 shares of common stock. The options have an exercise price of $2.48 per share and expire on June 17, 2036. The award vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued service as a director. Following this grant, De Vre holds 66,350 stock options directly.
CODEXIS, INC. director Raymond De Vre reported an open-market sale of common stock primarily to cover taxes from recently vested equity awards. He sold 2,605 shares at $2.37 per share on June 11, 2026. After this transaction, he holds 84,811 shares directly, including 31,897 Restricted Stock Units, so he retains a substantial continuing stake in the company.
Codexis, Inc. reported sharply improved results for the quarter ended March 31, 2026, with total revenue rising to $15.2 million from $7.5 million a year earlier as both product sales and research and development revenue grew. Product revenue increased to $7.2 million, while research and development revenue jumped to $8.1 million, largely from recognizing deferred revenue under a Merck licensing agreement and ECO Synthesis evaluation services.
Operating loss narrowed to $8.0 million from $20.5 million, aided by lower research and development and selling, general and administrative expenses, including reduced headcount and stock-based compensation. Net loss was $8.7 million, or $0.10 per share, compared with $20.7 million, or $0.25 per share, in the prior-year period.
Codexis ended the quarter with $36.6 million in cash and cash equivalents and $28.6 million in short-term investments, totaling $65.1 million in liquidity, and working capital of $64.8 million. Long-term debt was $40.5 million, primarily from the five-year Innovatus Loan, which carries an effective interest rate of 12.7%. The company also maintains an at-the-market equity program with $26.4 million of capacity remaining and believes existing resources and expected revenue will fund operations for at least the next 12 months while it advances its ECO Synthesis RNAi manufacturing platform and small-molecule biocatalysis business.
Codexis, Inc. reported first quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, driven by higher product and research and development revenue. The company’s net loss narrowed to $8.7 million from $20.7 million, with loss per share improving to $0.10 from $0.25.
Codexis ended the quarter with $65.1 million in cash and related investments and reiterated its full-year 2026 financial guidance. Management highlighted upcoming presentations at the TIDES USA meeting showcasing new data for its ECO Synthesis manufacturing platform, which targets scalable enzymatic production of complex RNA therapeutics.
Codexis, Inc. ownership update: Opaleye Management Inc., together with Opaleye, L.P. and James Silverman, reports beneficial ownership of 6,785,000 shares of Codexis common stock, representing 7.47% of the class. The filing states this includes 120,000 shares held in separate managed accounts. The filing cites 90,869,349 common shares outstanding as of 03/05/2026 as the basis for the percentage.
Codexis, Inc. is asking stockholders to vote at a virtual annual meeting on June 17, 2026. Investors will elect three Class I directors—Stephen G. Dilly, Raymond De Vré, and Rahul Singhvi—for terms running to the 2029 meeting, ratify KPMG LLP as independent auditor for 2026, and approve, on an advisory basis, executive pay.
Stockholders of record at the close of business on April 20, 2026, when 90,896,567 common shares were outstanding, may vote online, by phone, or by mail. The board is classified into three staggered groups and determined most directors to be independent under Nasdaq rules. The filing also outlines committee structures, director compensation, major shareholders, and audit fees paid to KPMG and former auditor BDO.